Trials / Completed
CompletedNCT01852513
Allergic Rhinitis Changes the Sinus Microbiome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QNASL | |
| DRUG | Placebo nasal spray |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-11-01
- Completion
- 2014-06-01
- First posted
- 2013-05-13
- Last updated
- 2020-10-09
- Results posted
- 2020-10-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01852513. Inclusion in this directory is not an endorsement.